{"DataElement":{"publicId":"3945713","version":"1","preferredName":"Naranjo Checklist Adverse Reaction Improvement Post Discontinued Drug Or Antagonist Administered Indicator","preferredDefinition":"Indicator that signifies whether or not the adverse reaction improved when the drug was discontinued or specific antagonist was given.","longName":"NARANJO_ADR_IMPROV_IND","context":"DCI","contextVersion":"1","DataElementConcept":{"publicId":"3945607","version":"1","preferredName":"Naranjo Checklist Adverse Reaction Improvement Post Discontinued Drug Or Antagonist Administered","preferredDefinition":"A questionnaire developed by Naranjo et al that is designed to assess the likelihood that an adverse event is due to the drug administered rather than the result of other factors._Any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, syndrome, or disease, temporally associated with the use of a medical product or procedure, regardless of whether or not it is considered related to the product or procedure (attribution of unrelated, unlikely, possible, probable, or definite). The concept refers to events that could be medical product related, dose related, route related, patient related, caused by an interaction with another therapy or procedure, or caused by opioid initiation or dose escalation. The term also is referred to as an adverse experience. The old term Side Effect is retired and should not be used._A condition superior to an earlier condition._Happening at a time subsequent to a reference time; later in time or order._To stop or end, permanently or temporarily._Any natural, endogenously-derived, synthetic or semi-synthetic compound with pharmacologic activity. A pharmacologic substance has one or more specific mechanism of action(s) through which it exerts one or more effect(s) on the human or animal body. They can be used to potentially prevent, diagnose, treat or relieve symptoms of a disease. Formulation specific agents and some combination agents are also classified as pharmacologic substances._An article used to connect words, phrases, or clauses representing alternatives; used to connect alternative terms for the same thing; used in correlation; used to correct or rephrase what was previously said; otherwise._In medicine, a substance that stops the action or effect of another substance. For example, a drug that blocks the stimulating effect of estrogen on a tumor cell is called an estrogen receptor antagonist._The act of having given something (e.g., a medication or test).","longName":"3945598v1.0:3945605v1.0","context":"DCI","contextVersion":"1","ObjectClass":{"publicId":"3945598","version":"1","preferredName":"Naranjo Adverse Drug Reaction Probability Scale","preferredDefinition":"A questionnaire developed by Naranjo et al that is designed to assess the likelihood that an adverse event is due to the drug administered rather than the result of other factors.","longName":"C111889","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Naranjo Adverse Drug Reaction Probability Scale","conceptCode":"C111889","definition":"A questionnaire developed by Naranjo et al that is designed to assess the likelihood that an adverse event is due to the drug administered rather than the result of other factors.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":"NCI Thesaurus","workflowStatus":"RELEASED","registrationStatus":"Application","id":"EA71051E-C01E-9CF8-E040-BB89AD433955","latestVersionIndicator":"Yes","beginDate":"2013-11-05","endDate":null,"createdBy":"COOPERM","dateCreated":"2013-11-05","modifiedBy":"ONEDATA","dateModified":"2013-11-05","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"Property":{"publicId":"3945605","version":"1","preferredName":"Adverse Event Improvement Post Discontinued Pharmacologic Substance Or Antagonist Administered","preferredDefinition":"Any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, syndrome, or disease, temporally associated with the use of a medical product or procedure, regardless of whether or not it is considered related to the product or procedure (attribution of unrelated, unlikely, possible, probable, or definite). The concept refers to events that could be medical product related, dose related, route related, patient related, caused by an interaction with another therapy or procedure, or caused by opioid initiation or dose escalation. The term also is referred to as an adverse experience. The old term Side Effect is retired and should not be used.:A condition superior to an earlier condition.:Happening at a time subsequent to a reference time; later in time or order.:Discontinued; stopped permanently or temporarily.:Any natural, endogenously-derived, synthetic or semi-synthetic compound with pharmacologic activity. A pharmacologic substance has one or more specific mechanism of action(s) through which it exerts one or more effect(s) on the human or animal body. They can be used to potentially prevent, diagnose, treat or relieve symptoms of a disease. Formulation specific agents and some combination agents are also classified as pharmacologic substances.:An article used to connect words, phrases, or clauses representing alternatives; used to connect alternative terms for the same thing; used in correlation; used to correct or rephrase what was previously said; otherwise.:In medicine, a substance that stops the action or effect of another substance. For example, a drug that blocks the stimulating effect of estrogen on a tumor cell is called an estrogen receptor antagonist.:The act of having given something (e.g., a medication or test).","longName":"3945605v1.0","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Adverse Event","conceptCode":"C41331","definition":"Any unfavorable or unintended disease, sign, or symptom (including an abnormal laboratory finding) that is temporally associated with the use of a medical treatment or procedure, and that may or may not be considered related to the medical treatment or procedure. Such events can be related to the intervention, dose, route of administration, patient, or caused by an interaction with another drug(s) or procedure(s).","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"7"},{"longName":"Improvement","conceptCode":"C94226","definition":"A condition superior to an earlier condition.","evsSource":"CTCAE_CODE","primaryIndicator":"No","displayOrder":"6"},{"longName":"Post","conceptCode":"C38008","definition":"Happening at a time subsequent to a reference time; later in time or order.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"5"},{"longName":"Discontinue","conceptCode":"C25484","definition":"To stop or end, permanently or temporarily.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"4"},{"longName":"Pharmacologic Substance","conceptCode":"C1909","definition":"Any natural, endogenously-derived, synthetic or semi-synthetic compound with pharmacologic activity. A pharmacologic substance has one or more specific mechanism of action(s) through which it exerts one or more effect(s) on the human or animal body. They can be used to potentially prevent, diagnose, treat or relieve symptoms of a disease. Formulation specific agents and some combination agents are also classified as pharmacologic substances.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"3"},{"longName":"Or","conceptCode":"C37998","definition":"An article used to connect words, phrases, or clauses representing alternatives; used to connect alternative terms for the same thing; used in correlation; used to correct or rephrase what was previously said; otherwise.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"2"},{"longName":"Antagonist","conceptCode":"C94373","definition":"In medicine, a substance that stops the action or effect of another substance. For example, a drug that blocks the stimulating effect of estrogen on a tumor cell is called an estrogen receptor antagonist.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Administered","conceptCode":"C25382","definition":"The act of having given something (e.g., a medication or test).","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"EA716069-57DD-7546-E040-BB89AD4333D9","latestVersionIndicator":"Yes","beginDate":"2013-11-05","endDate":null,"createdBy":"COOPERM","dateCreated":"2013-11-05","modifiedBy":"ONEDATA","dateModified":"2013-11-05","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"ConceptualDomain":{"publicId":"2008517","version":"1","preferredName":"Adverse Events","preferredDefinition":"any unfavorable symptoms, signs, or disease temporally associated with the use of a medical\r\ntreatment or procedure that may or may not be considered related to the medical\r\ntreatment or procedure.","longName":"AE","context":"CTEP","contextVersion":"2.31","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"AB51E03C-635E-5672-E034-0003BA12F5E7","latestVersionIndicator":"Yes","beginDate":"2002-09-23","endDate":null,"createdBy":"MSUPLEY","dateCreated":"2002-09-23","modifiedBy":"SBR","dateModified":"2003-10-29","changeDescription":"Definition copied from CTC Manual.","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":"Naranjo ADR Scale:Naranjo CA, Busto U, Sellers EM, et al. A method for estimating the probability of adverse drug reactions. Clin Pharmacol Ther. 1981;30:239-245.","workflowStatus":"RELEASED","registrationStatus":"Application","id":"EA716069-57EE-7546-E040-BB89AD4333D9","latestVersionIndicator":"Yes","beginDate":"2013-11-05","endDate":null,"createdBy":"COOPERM","dateCreated":"2013-11-05","modifiedBy":"SBR","dateModified":"2016-06-06","changeDescription":"Created for DCRI study per request by T.Locklear. mc 11/5/13","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"ValueDomain":{"publicId":"3945561","version":"1","preferredName":"Naranjo Yes No Dont Know Indicator","preferredDefinition":"An event, entity or condition that typically characterizes a prescribed environment or situation and determines or aids in determining whether certain stated circumstances exist or criteria are satisfied.","longName":"3945561v1.0","context":"DCI","contextVersion":"1","type":"Enumerated","dataType":"CHARACTER","minLength":"2","maxLength":"12","minValue":null,"maxValue":null,"decimalPlace":null,"PermissibleValues":[{"value":"I don't know","valueDescription":"Don't Know/Refused","ValueMeaning":{"publicId":"2654058","version":"1","preferredName":"Don't Know/Refused","longName":"2654058","preferredDefinition":"The answer is not known by the person answering.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Does Not Know","conceptCode":"C67142","definition":"The answer is not known by the person answering.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"32BD33B1-0E11-3D3A-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2007-06-12","endDate":null,"createdBy":"UMLLOADER_TOBACCO","dateCreated":"2007-06-12","modifiedBy":"TSESU","dateModified":"2023-03-23","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"EA71051E-BFB7-9CF8-E040-BB89AD433955","beginDate":"2013-11-05","endDate":null,"createdBy":"COOPERM","dateCreated":"2013-11-05","modifiedBy":"ONEDATA","dateModified":"2013-11-05","deletedIndicator":"No"},{"value":"No","valueDescription":"No ","ValueMeaning":{"publicId":"2567170","version":"1","preferredName":"No","longName":"2567170","preferredDefinition":"The non-affirmative response to a question.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"No","conceptCode":"C49487","definition":"The non-affirmative response to a question.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE87-D36F-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2003-11-13","endDate":null,"createdBy":"SBREXT","dateCreated":"2003-11-13","modifiedBy":"SOKKERL","dateModified":"2023-12-05","changeDescription":"Updated to add NCIt concept relationship. Updated VM Short Name to be the Public ID to be consistent with current convention for VM Short Name - DW 10-03-2022","administrativeNotes":"2022.12.29 Alt VM added per ticket request CADSR0001837. ak","unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"EA71051E-BFC2-9CF8-E040-BB89AD433955","beginDate":"2013-11-05","endDate":null,"createdBy":"COOPERM","dateCreated":"2013-11-05","modifiedBy":"ONEDATA","dateModified":"2013-11-05","deletedIndicator":"No"},{"value":"Yes","valueDescription":"Yes","ValueMeaning":{"publicId":"3945562","version":"1","preferredName":"Yes","longName":"3945562","preferredDefinition":"The affirmative response to a question.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Yes","conceptCode":"C49488","definition":"The affirmative response to a question.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"EA71051E-BFCC-9CF8-E040-BB89AD433955","latestVersionIndicator":"Yes","beginDate":"2013-11-05","endDate":null,"createdBy":"COOPERM","dateCreated":"2013-11-05","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"EA71051E-BFE4-9CF8-E040-BB89AD433955","beginDate":"2013-11-05","endDate":null,"createdBy":"COOPERM","dateCreated":"2013-11-05","modifiedBy":"ONEDATA","dateModified":"2013-11-05","deletedIndicator":"No"}],"ConceptualDomain":{"publicId":"2008538","version":"1","preferredName":"Therapies","preferredDefinition":"actions or administration of therapeutic agents to produce an effect that is intended to alter the course of a pathologic process (NCI).","longName":"TX","context":"CTEP","contextVersion":"2.31","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B214D04D-9F05-1CA5-E034-0003BA12F5E7","latestVersionIndicator":"Yes","beginDate":"2002-12-18","endDate":null,"createdBy":"MSUPLEY","dateCreated":"2002-12-18","modifiedBy":"SBR","dateModified":"2003-10-29","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"RepresentationTerm":{"publicId":"2320047","version":"1","preferredName":"Indicator","preferredDefinition":"An event, entity or condition that typically characterizes a prescribed environment or situation. Indicators determine or aid in determining whether or not certain stated circumstances exist or criteria are satisfied. (On-line Medical Dictionary)","longName":"C25180","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Indicator","conceptCode":"C25180","definition":"An event, entity or condition that typically characterizes a prescribed environment or situation and determines or aids in determining whether certain stated circumstances exist or criteria are satisfied.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":"NCI Thesaurus","workflowStatus":"RELEASED","registrationStatus":"Standard","id":"FC6EF0D8-521A-6865-E034-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2005-07-25","endDate":null,"createdBy":"REEVESD","dateCreated":"2005-07-25","modifiedBy":"ONEDATA","dateModified":"2005-07-25","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":"Naranjo ADR Scale:Naranjo CA, Busto U, Sellers EM, et al. A method for estimating the probability of adverse drug reactions. Clin Pharmacol Ther. 1981;30:239-245.","workflowStatus":"RELEASED","registrationStatus":"Application","id":"EA71051E-BF96-9CF8-E040-BB89AD433955","latestVersionIndicator":"Yes","beginDate":"2013-11-05","endDate":null,"createdBy":"COOPERM","dateCreated":"2013-11-05","modifiedBy":"PWEST","dateModified":"2015-11-02","changeDescription":"Created for DCRI study per request by T.Locklear. mc 11/5/13","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"ClassificationSchemes":[{"publicId":"3835419","version":"1","longName":"Pharmacovigilance-Gabapentin/Pregabalin","context":"DCI","ClassificationSchemeItems":[{"publicId":"3938731","version":"1","longName":"Naranjo Checklist","context":"DCI"}]}],"AlternateNames":[],"ReferenceDocuments":[{"name":"Did the adverse reaction impr","type":"Preferred Question Text","description":"Did the adverse reaction improve when the drug was discontinued or a specific antagonist was given?","url":null,"context":"DCI"}],"origin":"Naranjo ADR Scale:Naranjo CA, Busto U, Sellers EM, et al. A method for estimating the probability of adverse drug reactions. Clin Pharmacol Ther. 1981;30:239-245.","workflowStatus":"RELEASED","registrationStatus":"Application","id":"EA71051E-C393-9CF8-E040-BB89AD433955","latestVersionIndicator":"Yes","beginDate":"2013-11-05","endDate":null,"createdBy":"COOPERM","dateCreated":"2013-11-05","modifiedBy":"REEVESD","dateModified":"2014-11-14","changeDescription":"Created for DCRI study per request by T.Locklear. mc 11/5/13","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"}}